Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNTHNASDAQ:MRVINYSE:VCXBNASDAQ:VECT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNTHDianthus Therapeutics$18.31-5.1%$19.12$13.37▼$32.27$588.85M1.36280,200 shs272,904 shsMRVIMaravai LifeSciences$2.13-5.8%$2.07$1.67▼$10.03$575.53M0.252.33 million shs992,677 shsVCXB10X Capital Venture Acquisition Corp. III$11.07$11.05$10.48▼$12.99$146.01M0.0743,760 shs16,992 shsVECTVectivBio$16.85$16.85$4.25▼$16.98$573.24M0.11N/AN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNTHDianthus Therapeutics0.00%-2.86%-2.35%-14.16%-27.23%MRVIMaravai LifeSciences0.00%-10.88%+8.67%-13.06%-72.97%VCXB10X Capital Venture Acquisition Corp. III0.00%0.00%0.00%0.00%+0.73%VECTVectivBio0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDNTHDianthus Therapeutics1.3745 of 5 stars3.60.00.00.02.70.80.0MRVIMaravai LifeSciences4.0194 of 5 stars3.13.00.04.42.00.81.3VCXB10X Capital Venture Acquisition Corp. IIIN/AN/AN/AN/AN/AN/AN/AN/AVECTVectivBioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNTHDianthus Therapeutics 3.13Buy$53.00189.46% UpsideMRVIMaravai LifeSciences 2.25Hold$6.64211.68% UpsideVCXB10X Capital Venture Acquisition Corp. III 0.00N/AN/AN/AVECTVectivBio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VCXB, DNTH, MRVI, and VECT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025DNTHDianthus TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$58.00 ➝ $50.005/13/2025DNTHDianthus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.005/13/2025MRVIMaravai LifeSciencesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.005/13/2025MRVIMaravai LifeSciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$3.00 ➝ $2.003/25/2025MRVIMaravai LifeSciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$7.00 ➝ $5.003/21/2025MRVIMaravai LifeSciencesStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.003/21/2025MRVIMaravai LifeSciencesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$8.00 ➝ $2.50(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNTHDianthus Therapeutics$6.52M90.26N/AN/A$11.40 per share1.61MRVIMaravai LifeSciences$241.86M2.24$0.05 per share41.71$3.14 per share0.68VCXB10X Capital Venture Acquisition Corp. IIIN/AN/A$0.06 per share176.88($1.49) per shareN/AVECTVectivBio$27.34M20.97N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNTHDianthus Therapeutics-$43.56M-$2.88N/AN/AN/A-1,250.32%-21.68%-20.88%8/6/2025 (Estimated)MRVIMaravai LifeSciences-$119.03M-$1.14N/AN/AN/A-81.13%-6.61%-3.45%8/6/2025 (Estimated)VCXB10X Capital Venture Acquisition Corp. III$700KN/A0.00∞N/AN/AN/AN/AN/AVECTVectivBio-$93.74MN/A0.00∞N/AN/AN/AN/AN/ALatest VCXB, DNTH, MRVI, and VECT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025DNTHDianthus Therapeutics-$0.86-$0.82+$0.04-$0.82$0.81 million$1.16 million5/12/2025Q1 2025MRVIMaravai LifeSciences-$0.07-$0.08-$0.01-$0.21$44.01 million$46.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNTHDianthus TherapeuticsN/AN/AN/AN/AN/AMRVIMaravai LifeSciencesN/AN/AN/AN/AN/AVCXB10X Capital Venture Acquisition Corp. IIIN/AN/AN/AN/AN/AVECTVectivBioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNTHDianthus TherapeuticsN/A18.3018.30MRVIMaravai LifeSciences0.8910.749.94VCXB10X Capital Venture Acquisition Corp. IIIN/AN/AN/AVECTVectivBioN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNTHDianthus Therapeutics47.53%MRVIMaravai LifeSciences50.25%VCXB10X Capital Venture Acquisition Corp. III13.25%VECTVectivBioN/AInsider OwnershipCompanyInsider OwnershipDNTHDianthus Therapeutics8.15%MRVIMaravai LifeSciences2.11%VCXB10X Capital Venture Acquisition Corp. III82.47%VECTVectivBio9.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNTHDianthus Therapeutics8032.16 million24.70 millionOptionableMRVIMaravai LifeSciences610254.66 million250.94 millionOptionableVCXB10X Capital Venture Acquisition Corp. III413.19 million2.31 millionNot OptionableVECTVectivBio3034.02 millionN/ANo DataVCXB, DNTH, MRVI, and VECT HeadlinesRecent News About These CompaniesIronwood’s shares sink as FDA demands new trial for lead drugApril 15, 2025 | msn.comA brain biotech launches with Roche’s spare partsFebruary 13, 2025 | biopharmadive.comAravax Continues International Expansion with Appointment of Aled Williams as Chief Business OfficerJanuary 21, 2025 | markets.businessinsider.comCDR-Life Appoints Sarah Holland, PhD, as Chief Business OfficerDecember 5, 2024 | finance.yahoo.comRecent advances in clinical practice: mastering the challenge—managing IBS symptoms in IBDNovember 12, 2024 | gut.bmj.comGraft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsightSeptember 23, 2024 | finance.yahoo.comEtherio Group: 2024 CMI 25September 21, 2024 | meetingsnet.comCompare with VectivBio Holding AG (VECT)May 29, 2024 | msn.comenGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of DirectorsMay 15, 2024 | finance.yahoo.comVicore Pharma Holding: Vicore Expands and Strengthens its Board of DirectorsMay 14, 2024 | finanznachrichten.deVicore Expands and Strengthens its Board of DirectorsMay 14, 2024 | finance.yahoo.comShort Bowel Syndrome Market by 2032: Forecast Report Estimates Significant GrowthApril 5, 2024 | uk.finance.yahoo.comFDA approves DMD treatment from ItalfarmacoMarch 31, 2024 | cen.acs.orgPipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpointsMarch 18, 2024 | msn.comIronwood Nabs Phase III Win, Still Sees Stock NosediveMarch 1, 2024 | biospace.comIronwood felled by mixed data in short bowel syndrome trialMarch 1, 2024 | pharmaphorum.comUPDATE 3-Ironwood's bowel disease drug meets main goal of late-stage studyMarch 1, 2024 | msn.comIronwood's bowel disease treatment meets main goal in late-stage trialFebruary 29, 2024 | reuters.comWhy Is Gastrointestinal Healthcare Focused Ironwood Pharmaceuticals Stock Sinking On Thursday?February 29, 2024 | benzinga.comOnly two sleeps left until February 31!February 29, 2024 | ft.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVCXB, DNTH, MRVI, and VECT Company DescriptionsDianthus Therapeutics NASDAQ:DNTH$18.31 -0.98 (-5.08%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$18.30 -0.01 (-0.08%) As of 06/13/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Maravai LifeSciences NASDAQ:MRVI$2.13 -0.13 (-5.75%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.12 -0.01 (-0.47%) As of 06/13/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.10X Capital Venture Acquisition Corp. III NYSE:VCXB10X Capital Venture Acquisition Corp. III does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to identify business opportunities in the field of consumer internet, e-commerce, software, healthcare, transportation/mobility, financial services, artificial intelligence, automation, data science, and Software-as-a-Service. The company was incorporated in 2021 and is based in New York, New York. 10X Capital Venture Acquisition Corp. III operates as a subsidiary of 10X Capital SPAC Sponsor III LLC.VectivBio NASDAQ:VECT$16.85 0.00 (0.00%) As of 06/13/2025VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
